Delivery Order SPE2DB22D2005-SPE2DB26FJET9
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,227.36 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens. The contract, which is non-set-aside and competitively awarded, employs firm fixed-price pricing and was awarded on August 13, 2025, with an ultimate completion date of August 14, 2025. AmerisourceBergen will perform this delivery from its corporate headquarters in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a $4,038.26 delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens on June 13, 2025, with an ultimate completion date of June 16, 2025. This firm fixed-price, competitively awarded contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,686.79 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/ML 3ML insulin pens on September 2, 2025, with an ultimate completion date of September 3, 2025. This competitively awarded, non-set-aside order utilizes firm fixed pricing and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens with a ceiling value of $4,398.30. The contract is structured as a firm fixed price delivery order with no set-aside designation, indicating competitive award. Performance will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion...
- The Defense Logistics Agency awarded a $1,505.59 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 through December 2026. The place of performance is listed as Conshohocken, Pennsylvania, with an ultimate completion...
- The Defense Logistics Agency (DLA) awarded a $2,859.79 delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/ML 3ML insulin pens under a firm fixed-price contract type. The award, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a non-set-aside competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is a child contract issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,247.31 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens. The contract, awarded on September 5, 2025, with an ultimate completion date of September 8, 2025, was competitively awarded with no set-aside designation. This delivery order operates under a firm fixed price arrangement and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,022.80 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens. This competitively awarded, firm fixed-price contract was executed on September 16, 2025, with an ultimate completion date of September 17, 2025. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $1,367.70 delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin pens on September 11, 2025, with completion scheduled for September 12, 2025. This non-set-aside, competitively awarded contract represents a firm fixed price delivery against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,400.29 on June 2, 2025, for the supply of Lantus SoloStar 100 Unit/ml 3ml insulin pens. This firm fixed-price, competitively awarded contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 through December 2026. The product will be delivered to...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB26FJET9Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,274.88 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/ML insulin pens on October 29, 2025, with an ultimate completion date of October 30, 2025. This competitively awarded, non-set-aside contract employs firm fixed price terms and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp serves as a major pharmaceutical distributor and critical federal medical procurement vendor, supplying comprehensive pharmaceutical products and medical supplies to support military and veteran healthcare systems. As a prime IDC holder with DLA, the company maintains the capability to deliver specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains to customers including the Defense Health Agency and U.S. Coast Guard. This specific delivery order for insulin reflects the company's ongoing role in fulfilling pharmaceutical needs within the DLA's pharmaceutical supply chain, with the product intended for military healthcare programs and beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 10/29/25 |